EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

Author's Avatar
Dec 02, 2021

Combined company will operate as EOM Pharmaceuticals Holdings, Inc. advancing a pipeline of novel immunomodulatory agents including EOM613 currently in clinical trials in Brazil as a potential treatment for severely ill COVID-19 patients

Combined company plans to continue at this time to trade on the OTC Markets

PR Newswire